https://scholars.lib.ntu.edu.tw/handle/123456789/190632
標題: | Increased Rosuvastatin Dose versus Concomitant Fenofibrate and Rosuvastatin Therapy to Achieve Lipid Goal in Patients with Diabetes or Atherosclerosis with Metabolic Syndrome | 作者: | Chen, Yeh-Peng Chen, Yeh-Peng Chang, Kuan-Cheng Chang, Kuan-Cheng Tseng, Wei-Kung Tseng, Wei-Kung Yin, Wei-Hsian Yin, Wei-Hsian Chen, Jaw-Wen Chen, Jaw-Wen Lee, Yuan-Teh Lee, Yuan-Teh Wu, Chau-Chung Wu, Chau-Chung |
關鍵字: | Combination therapy;Diabetes;Fenofibrate;Metabolic syndrome;Monotherapy;Statin | 公開日期: | 2013 | 卷: | 29 | 期: | 5 | 起(迄)頁: | 421-428 | 來源出版物: | Acta Cardiol. Sin. | 摘要: | Purpose: We aimed to ascertain whether increased rosuvastatin dose is non-inferior to concomitant fenofibrate and rosuvastatin therapy in patients with diabetes or atherosclerosis with metabolic syndrome. Methods: After treatment with rosuvastatin 5 mg/day for 12 weeks, 112 patients were randomly assigned to receive either 10 mg/day rosuvastatin (group A) or 80 mg/day supra-film coated fenofibrate plus 5 mg/day rosuvastatin (group B). The therapy effects were evaluated by measuring the serum lipid profile, liver and muscle enzymes, and renal function after the treatment period. Results: After the treatment, the total cholesterol, high-density-lipoprotein cholesterol (HDL-C), non HDL-C, low-density-lipoprotein cholesterol (LDL-C), and triglyceride were comparable between the 2 groups. The change in the non-HDL-C were -7.39 +/- 26.58 (-6.62%) and -0.68 +/- 24.49 (-1.19%) mg/dl (p = 0.28); and the change in the triglyceride were -36.61 +/- 62.51 (-14.00%) and -44.77 +/- 77.35 (-23.17%) mg/dl (p = 0.64), respectively. While 41.37% of group A and 38.69% of group B achieved their LDL-C goal (< 100 mg/dl) (p = 0.79), 37.26% of group A and 42.31% of group B achieved their triglyceride goal (< 150 mg/dl) (p = 0.53), respectively. The changes in the serum transaminase and creatinine phosphokinase were similar between the 2 groups. Conclusions: After 5 mg/day of rosuvastatin, the lipid profile in patients with diabetes or atherosclerotic vascular diseases with metabolic syndrome could be improved by increasing rosuvastatin dose, and the resultant decrease of non-HDL and triglyceride were similar to those obtained with combination therapy. Both therapies were safe and feasible. |
URI: | http://ntur.lib.ntu.edu.tw//handle/246246/259519 |
顯示於: | 醫學系 |
檔案 | 描述 | 大小 | 格式 | |
---|---|---|---|---|
index.html | 23.1 kB | HTML | 檢視/開啟 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。